Homeopathic Clinical Drug Proving Trial on Rhodiola Rosea
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 2, Pages 1327-1332
The main aim of the study is to assess whether Rhodiola rosea in the potency C 1-4 nitites more
characteristic homeopathic symptoms during proving after three days upto one week, compared
to a placebo in Hypertensive and Anxiety/ Depression prone volunteers.
Secondary aims are to develop and to test a qualitative analysis methodology on which to base a
definition for drug-specific (characteristic) symptoms and to compile a profile of characteristic
homeopathic proving symptoms of the drug being trialed for therapeutic purposes.
This study protocol adapts the traditional homeopathic drug proving methodology to a modern
clinical trial design.
- Article View: 316
- PDF Download: 311